Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Penpulimab Plus Gemcitabine and Anlotinib in the Treatment of Metastatic Nasopharyngeal Cancer, A Single Arm, Open-label, Phase Ib Clinical Trial

NCT06886347 is registered in ClinicalTrials.gov with Chen Xiaozhong as lead sponsor.

NCT NCT06886347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06886347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Penpulimab Plus Gemcitabine and Anlotinib in the Treatment of Metastatic Nasopharyngeal Cancer, A Single Arm, Open-label, Phase Ib Clinical Trial
Lead sponsor
Chen Xiaozhong
Phase
Phase 1
Overall status
Recruiting
Start date
July 7, 2023
Completion date
April 1, 2026
Enrollment
47 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic nasopharyngeal carcinoma